- Data presented at EuroPCR 2023 build on prior study results demonstrating TriClip is a safe and effective therapy to treat leaky tricuspid valves
- Findings from the largest real-world dataset for tricuspid repair show device reduces tricuspid regurgitation and improves quality of life
ABBOTT PARK, Ill., May 17, 2023 — Abbott today announced late-breaking data that add to the body of clinical evidence supporting the benefits of the TriClip™ transcatheter edge-to-edge repair (TEER) system in treating patients with leaky tricuspid valves. Abbott's TriClip device is a first-of-its kind, minimally invasive device designed specifically for tricuspid heart valve repair.